Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
19 hedge funds and large institutions have $27.9M invested in Bellerophon Therapeutics, Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 8 closing their positions.
3,248% more capital invested
Capital invested by funds: $833K → $27.9M (+$27M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
24.12% more ownership
Funds ownership: 9.69% → 33.81% (+24%)
21% less funds holding
Funds holding: 24 → 19 (-5)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$3.24M |
| 2 |
Morgan Stanley
New York
|
+$3.13M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.11M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$110K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$25K |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$21.4K |
| 3 |
Millennium Management
New York
|
-$21K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.8K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$18K |
BLPH Hedge Fund Activity: Q1 2023 in Review
19 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2023, worth a combined $27.9M — up 3,248% from $833K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BLPH and 4 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $3.24M. The largest seller was HRT Financial, exiting entirely with an estimated $25K sold.
- 19 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2023, down from 24 in Q4 2022.
- Funds reported $27.9M of Bellerophon Therapeutics, Inc. stock for Q1 2023, up 3,248% quarter-over-quarter.
- 4 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2023 and 8 closed out, a net change of -4 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q1 2023 was Perceptive Advisors, an estimated $3.24M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q1 2023 was HRT Financial, an estimated $25K sold.
Based on aggregated 13F filings for Q1 2023.